These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32884926)

  • 1. Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review.
    Vozmediano-Chicharro R; Blasco Hernández P; Madurga-Patuel B
    Res Rep Urol; 2020; 12():321-330. PubMed ID: 32884926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which anticholinergic drug for overactive bladder symptoms in adults.
    Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
    Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxybutynin topical gel in the treatment of overactive bladder.
    Davila GW
    Open Access J Urol; 2010 Jun; 2():91-8. PubMed ID: 24198618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of oxybutynin chloride topical gel for overactive bladder.
    Lucente VR; Staskin DR; De E
    Open Access J Urol; 2011 Apr; 3():35-42. PubMed ID: 24198634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overactive bladder in the elderly: a guide to pharmacological management.
    Staskin DR
    Drugs Aging; 2005; 22(12):1013-28. PubMed ID: 16363885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transdermal drug delivery treatment for overactive bladder.
    Dmochowski RR; Starkman JS; Davila GW
    Int Braz J Urol; 2006; 32(5):513-20. PubMed ID: 17081319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of transdermal oxybutynin in the treatment of overactive bladder.
    Sahai A; Mallina R; Dowson C; Larner T; Khan MS
    Int J Clin Pract; 2008 Jan; 62(1):167-70. PubMed ID: 18173821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal oxybutynin for overactive bladder.
    Davila GW; Starkman JS; Dmochowski RR
    Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxybutynin gel for the treatment of overactive bladder.
    Gomelsky A; Dmochowski RR
    Expert Opin Pharmacother; 2012 Jun; 13(9):1337-43. PubMed ID: 22607010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin.
    Gamble T; Sand P
    Patient Prefer Adherence; 2008 Feb; 2():349-56. PubMed ID: 19920982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal oxybutynin: sticking to the facts.
    Cartwright R; Cardozo L
    Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of oxybutynin in transdermal patches for treating overactive bladder.
    Salinas-Casado J; Esteban-Fuertes M; Serrano O; Galván J
    Actas Urol Esp; 2015 Dec; 39(10):599-604. PubMed ID: 26321038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which anticholinergic drug for overactive bladder symptoms in adults.
    Hay-Smith J; Herbison P; Ellis G; Morris A
    Cochrane Database Syst Rev; 2005 Jul; (3):CD005429. PubMed ID: 16034974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials.
    Dmochowski RR; Nitti V; Staskin D; Luber K; Appell R; Davila GW
    World J Urol; 2005 Sep; 23(4):263-70. PubMed ID: 16151816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron--a new selective beta3agonist].
    Rechberger T; Kulik-Rechberger B; Miotła P; Wróbel A
    Ginekol Pol; 2014 Mar; 85(3):214-9. PubMed ID: 24783434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transdermal oxybutynin: a new treatment for overactive bladder.
    Davila GW
    Expert Opin Pharmacother; 2003 Dec; 4(12):2315-24. PubMed ID: 14640930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
    Herschorn S; Stothers L; Carlson K; Egerdie B; Gajewski JB; Pommerville P; Schulz J; Radomski S; Drutz H; Barkin J; Paradiso-Hardy F
    J Urol; 2010 May; 183(5):1892-8. PubMed ID: 20303119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal oxybutynin in the treatment of overactive bladder.
    Davila GW
    Clin Interv Aging; 2006; 1(2):99-105. PubMed ID: 18044106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.